Small Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast
For decades, the treatment landscape of small-cell lung cancer (SCLC) has been dominated by chemotherapy or chemoradiotherapy. In 2018, BristolMyers Squibb’s Opdivo became the first immune checkpoint inhibitor to be approved in the United States for extensive-stage SCLC. In 2019, Merck & Co.’s Keytruda was approved in the same setting as Opdivo in the United States and Roche / Genentech / Chugai’s Tecentriq was approved in combination with chemotherapy as a treatment for extensive-stage SCLC in the seven major markets. In 2020, AstraZeneca's Imfinzi was approved in the same setting as Tecentriq across all major markets, and the FDA approval of PharmaMar’s Zepzelca marked the entry of a novel chemotherapy agent for patients. However, despite the flurry of approvals, a significant unmet need remains for more efficacious therapeutic options. Despite the comparatively small market size, the modest late-phase pipeline looks set to further revolutionize SCLC treatment algorithms, with other novel agents enetering late-phase development such as Roche's anti-TIGIT MAb tiragolumab and Ipsen/Servier's liposomal irinotecan agent Onivyde.
Questions Answered
- How is SCLC managed, and how will the treatment paradigm evolve?
- What are the sizes of the drug-treatable SCLC populations and how will drug-treatment rates change over time?
- How will the recent approvals of immune checkpoint inhibitors for extensive-stage SCLC impact the market?
- What are the major unmet needs, and how will key emerging therapies shape the SCLC market over the ten-year forecast period?
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Scope:
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 19 country-specific interviews with experts and 210 country-specific surveys of medical oncologists treating SCLC.
Epidemiology: Diagnosed incidence of SCLC by country (segmented by limited-stage and extensive-stage disease).
Population segments in market forecast: Limited-stage, first-line extensive stage, second line, and third line.
Emerging therapies: Phase I/II: 11 drugs; Phase III: 6 drugs.
Table of contents
- Small Cell Lung Cancer - Landscape & Forecast - Disease Landscape & Forecast
- COVID-19
- Key Findings
- SCLC - Key Findings
- Key Updates
- December 2020
- November 2020
- July 2020
- May 2020
- March 2020
- Market Outlook
- Key Findings
- Market Share of Drug Classes for Small-Cell Lung Cancer: 2018
- Market Share of Drug Classes for Small-Cell Lung Cancer: 2028
- Drug-Treatable Population Share and Major-Market Sales Share in Small-Cell Lung Cancer: 2018
- Drug-Treatable Population Share and Major-Market Sales Share in Small-Cell Lung Cancer: 2028
- Population Positioning of Therapies in Small-Cell Lung Cancer
- Small-Cell Lung Cancer SWOT Analysis
- COVID-19: Areas of Potential Forecast Impact
- COVID-19: Areas of Potential Forecast Impact
- Market Drivers and Constraints
- What Factors Are Driving the Market for Small-Cell Lung Cancer?
- What Factors Are Constraining the Market for Small-Cell Lung Cancer?
- Major-Market Sales, by Population: 2018-2028
- PD-L1 Inhibitor Major-Market Sales, by Population: 2018-2028
- Major-Market Sales of Key Therapies for SCLC: 2018-2028
- Segment-Specific Trends
- Limited Stage, First Line
- Patient-Share Dynamics of Regimens in First-Line Limited-Stage SCLC, United States: 2018-2028
- Extensive Stage, First Line
- Patient-Share Dynamics of Regimens in First-Line Extensive-Stage SCLC, United States: 2018-2028
- Second and Third Line
- Patient-Share Dynamics of Key Regimens in Second-Line SCLC, United States: 2018-2028
- Patient-Share Dynamics of Key Regimens in Second-Line SCLC, Japan: 2018-2028
- Patient-Share Dynamics of Key Regimens in Third-Line SCLC, United States: 2018-2028
- Patient-Share Dynamics of Key Regimens in Third-Line SCLC, Japan: 2018-2028
- Key Findings
- Forecast
- Market Forecast Assumptions
- Market Forecast Dashboard
- Etiology and Pathophysiology
- Disease Overview
- Etiology
- Etiology of Small-Cell Lung Cancer
- Risk Factors for Developing Small-Cell Lung Cancer
- Pathophysiology
- Disease Characteristics
- Disease Development
- Clinical Staging and Risk-Classification
- Staging of Small-Cell Lung Cancer According to the TNM Classification System
- Stratification of Small-Cell Lung Cancer into Different Prognostic Groups, According to TNM Staging
- Signs and Symptoms
- Common Signs and Symptoms of Small-Cell Lung Cancer
- Key Pathways and Drug Targets
- Key Pathways in Small-Cell Lung Cancer
- Disease Overview
- Epidemiology
- Key Findings
- Key Updates
- Epidemiology Populations
- Disease Definition
- Methods
- Sources Used for Diagnosed Incidence of Small-Cell Lung Cancer
- Number of Diagnosed Incident Cases of Small-Cell Lung Cancer in the Major Pharmaceutical Markets, 2018-2028t
- Disease Definition
- Methods
- Sources Used for Stage Distribution of Small-Cell Lung Cancer
- Number of Diagnosed Incident Cases of Small-Cell Lung Cancer in the Major Pharmaceutical Markets by Stage Distribution, 2018-2028
- Definition
- Methods
- Sources Used for Recurrent Incidence of Small-Cell Lung Cancer
- Number of Recurrent Incident Cases of Small-Cell Lung Cancer in the Major Pharmaceutical Markets, 2018-2028
- Small-Cell Lung Cancer Patient Flow
- Drug-Treatable Cases of Small-Cell Lung Cancer: 2018-2028
- Drug-Treated Cases of Small-Cell Lung Cancer: 2018-2028
- Key Findings
- Current Treatment
- Key Findings
- Treatment Goals
- Key Endpoints Used in Clinical Trials for Small-Cell Lung Cancer
- Key Current Therapies
- Overview
- Mechanism of Action of Key Current Drug Classes Used for Small-Cell Lung Cancer
- Current Treatments Used for Small-Cell Lung Cancer
- Market Events Impacting the Use of Key Current Therapies for Small-Cell Lung Cancer
- Opdivo
- Key Results from Select Clinical Trials Investigating Opdivo for the Treatment of Small-Cell Lung Cancer
- Ongoing Clinical Development of Opdivo
- Key Ongoing Clinical Trials of Opdivo in the Treatment of Small-Cell Lung Cancer
- Expert Insight: Opdivo
- Keytruda
- Key Results from Select Clinical Trials Investigating Keytruda for the Treatment of Small-Cell Lung Cancer
- Ongoing Clinical Development of Keytruda
- Key Ongoing Clinical Trials of Keytruda in the Treatment of Small-Cell Lung Cancer
- Expert Insight: Keytruda
- Tecentriq
- Key Results from Select Clinical Trials Investigating Tecentriq for the Treatment of Small-Cell Lung Cancer
- Ongoing Clinical Development of Tecentriq
- Key Ongoing Clinical Trials of Tecentriq in the Treatment of Small-Cell Lung Cancer
- Expert Insight: Tecentriq
- Imfinzi
- Key Results from Select Clinical Trials Investigating Imfinzi for the Treatment of Small-Cell Lung Cancer
- Ongoing Clinical Development of Imfinzi
- Key Ongoing Clinical Trials of Imfinzi in the Treatment of Small-Cell Lung Cancer
- Expert Insight: Imfinzi
- Cytotoxic Agents
- Key Results from Select Clinical Trials Investigating Cytotoxic Agents for the Treatment of SCLC
- Expert Insight: Cytotoxic Agents
- Zepzelca
- Key Results from Select Clinical Trials Investigating Zepzelca for the Treatment of SCLC
- Ongoing Clinical Development of Zepzelca
- Key Ongoing Clinical Trials of Zepzelca in the Treatment of SCLC
- Expert Insight: Zepzelca
- Medical Practice
- Limited-Stage Small-Cell Lung Cancer
- First-Line Extensive-Stage Small-Cell Lung Cancer
- Second-Line Small-Cell Lung Cancer
- Third-Line Small-Cell Lung Cancer
- Country-Specific/Regional Small-Cell Lung Cancer Treatment Guidelines
- Patient Characteristics Influencing Drug Selection in Small-Cell Lung Cancer
- Treatment Decision Tree for Small-Cell Lung Cancer: United States
- Treatment Decision Tree for Small-Cell Lung Cancer: Europe
- Treatment Decision Tree for Small-Cell Lung Cancer: Japan
- Key Findings
- Unmet Need Overview
- Current and Future Attainment of Unmet Needs in Small-Cell Lung Cancer
- Top Unmet Needs in Small-Cell Lung Cancer: Current and Future Attainment
- Expert Insight: Unmet Need in Small-Cell Lung Cancer
- Emerging Therapies
- Key Findings
- Pipeline Trends in Small-Cell Lung Cancer
- Key Emerging Therapies
- Key Therapies in Development for Small-Cell Lung Cancer
- Estimated Market Authorization Dates of Key Emerging Therapies for the Treatment of Small-Cell Lung Cancer
- Key Results from Select Clinical Trials Investigating Tremelimumab for the Treatment of Small-Cell Lung Cancer
- Key Ongoing Clinical Trials of Tremelimumab in the Treatment of Small-Cell Lung Cancer
- Analysis of the Clinical Development Program for Tremelimumab
- Expert Insight: Tremelimumab
- Expectations for Market Authorization and Sales Opportunity of Tremelimumab in Small-Cell Lung Cancer
- Key Ongoing Clinical Trials of Tiragolumab in the Treatment of Small-Cell Lung Cancer
- Analysis of the Clinical Development Program for Tiragolumab
- Expert Insight: Tiragolumab
- Expectations for Market Authorization and Sales Opportunity of Tiragolumab in Small-Cell Lung Cancer
- Key Results from Select Clinical Trials Investigating RRx-001 for the Treatment of Small-Cell Lung Cancer
- Key Ongoing Clinical Trials of RRx-001 in the Treatment of Small-Cell Lung Cancer
- Analysis of the Clinical Development Program for RRx-001
- Expert Insight: RRx-001
- Expectations for Market Authorization and Sales Opportunity of RRx-001 in Small-Cell Lung Cancer
- Key Results from Select Clinical Trials Investigating Trilaciclib for the Treatment of Small-Cell Lung Cancer
- Key Ongoing Clinical Trials of Trilaciclib in the Treatment of Small-Cell Lung Cancer
- Analysis of the Clinical Development Program for Trilaciclib
- Expert Insight: Trilaciclib
- Expectations for Market Authorization and Sales Opportunity of Trilaciclib in Small-Cell Lung Cancer
- Key Results from Select Clinical Trials Investigating Onivyde for the Treatment of Small-Cell Lung Cancer
- Key Ongoing Clinical Trials of Onivyde in the Treatment of Small-Cell Lung Cancer
- Analysis of the Clinical Development Program for Onivyde
- Expert Insight: Onivyde
- Expectations for Market Authorization and Sales Opportunity of Onivyde in Small-Cell Lung Cancer
- Early-Phase Pipeline Analysis
- Select Compounds in Early-Phase Development for Small-Cell Lung Cancer
- Key Findings
- Access & Reimbursement Overview
- Region-Specific Reimbursement Practices
- Key Market Access Considerations in Small-Cell Lung Cancer: United States
- General Reimbursement Environment: United States
- Key Market Access Considerations in Small-Cell Lung Cancer: EU5
- General Reimbursement Environment: EU5
- Key Market Access Considerations in Small-Cell Lung Cancer: Japan
- General Reimbursement Environment: Japan
- Region-Specific Reimbursement Practices
- Appendix
- Key Abbreviations Related to Small-Cell Lung Cancer
- Brands, Marketers, and Generic Availability of Key Therapies for Small-Cell Lung Cancer: by Market
- Small-Cell Lung Cancer Bibliography
- COVID-19
Sudha Malhotra, M.S., Ph.D., is an analyst on the Oncology team at Clarivate. She is responsible for performing secondary market analysis, including patent research, pricing, and clinical trial assessment in the major pharmaceutical markets covering a wide range of oncology indications. She obtained her doctorate degree in life sciences from the National Institute of Immunology in New Delhi, India, and has authored several peer-reviewed journal articles. She holds a bachelor’s degree in microbiology and a master’s degree in biomedical sciences, both from the University of Delhi.
Atul Sharma, M.P.H., is an associate epidemiologist at DRG, part of Clarivate. He holds a master’s degree in public health from the School of Public Health, Post-Graduate Institute of Medical Education and Research, and a bachelor’s degree in dental surgery from MN DAV Dental College and Hospital.
Sorcha Cassidy, M.Res., Ph.D., is an associate director on the Oncology team at Clarivate. She manages a team of analysts who produce syndicated primary and secondary market research reports and custom analysis on a wide range of oncology indications. Dr. Cassidy also provides client support for all oncology products and has expertise in hematologic malignancies and CAR T-cell therapies. She has published oncology market assessment articles in Nature Reviews Drug Discovery. Previously, Dr. Cassidy was a market research manager at Janssen UK. She obtained her M.Res. and Ph.D. in immunology from Imperial College London, where she investigated the role of innate immune modulators (killer immunoglobulin-like receptors [KIRs]) on natural killer cells in various diseases.